BIOMARIN PHARMACEUTICAL (1BMRN.MI)
| Previous Close | 64.62 |
| Open | 64.18 |
| Bid | 64.90 x N/A |
| Ask | 65.36 x N/A |
| Day's Range | 64.18 - 64.18 |
| 52 Week Range | 62.90 - 91.38 |
| Volume | |
| Avg. Volume | 17 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Oct 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireBioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, October 29, 2024, at 4:30 p.m. ET to discuss third quarter 2024 financial results and provide a general business update.
Simply Wall St.High Growth Tech Stocks To Watch For Future Potential
Over the last 7 days, the market has remained flat, yet it is up 32% over the past year with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks with strong potential can be crucial for investors looking to capitalize on future opportunities.
- PR Newswire
BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that positive data from the CANOPY clinical program evaluating VOXZOGO® (vosoritide) in children with achondroplasia and other genetic skeletal conditions will be presented at the 16th International Skeletal Dysplasia Society meeting (ISDS) in Madrid, Sept. 18-21, 2024. These results include data showing that children with achondroplasia treated with VOXZOGO experienced meaningful improvements beyond height, such as in health-related qu
